Glanzmann's thrombasthenia secondary prevention

Jump to navigation Jump to search

Glanzmann's thrombasthenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glanzmann's thrombasthenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glanzmann's thrombasthenia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glanzmann's thrombasthenia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glanzmann's thrombasthenia secondary prevention

CDC on Glanzmann's thrombasthenia secondary prevention

Glanzmann's thrombasthenia secondary prevention in the news

Blogs on Glanzmann's thrombasthenia secondary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Glanzmann's thrombasthenia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]

Overview

DDAVP prevents bleeding after dental extraction and minor surgery in patients with milder platelet defects. Glanzmann's thrombasthenia patients need regular dental visits and must maintain good oral hygiene because the recurrence of gingival bleeding is more in them. These patient should avoid contact sports. Estrogens, platelet transfusion, antifibrinolytic agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention.

Secondary Prevention

DDAVP prevents bleeding after dental extraction and minor surgery in patients with milder platelet defects[1][2]. Glanzmann's thrombasthenia patients need regular dental visits and must maintain good oral hygiene because the recurrence of gingival bleeding is more in them. These patient should avoid contact sports. Estrogens, platelet transfusion, antifibrinolytic agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention. [3][4][5]

References

  1. Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaërt M, Mercier J (March 2002). "Management of dental extractions in patients with bleeding disorders". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93 (3): 247–50. PMID 11925531.
  2. Kosch A, Kehrel B, Nowak-Göttl U, Häberle J, Jürgens H (1999). "[Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin]". Klin Padiatr (in German). 211 (4): 198–200. doi:10.1055/s-2008-1043787. PMID 10472549.
  3. Varkey I, Rai K, Hegde AM, Vijaya MS, Oommen VI (March 2014). "Clinical Management of Glanzmann's Thrombasthenia: A Case Report". J Dent (Tehran). 11 (2): 242–7. PMC 4043557. PMID 24910701.
  4. Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
  5. Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y (January 2006). "Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents". Semin. Hematol. 43 (1 Suppl 1): S33–6. doi:10.1053/j.seminhematol.2005.11.009. PMID 16427383.